New HIV vaccine with a 97% antibody response rate in phase I human trials
The title seems to over-promise.> ...the vaccine successfully stimulated the production of the rare immune cells needed to generate antibodies against HIV in 97 percent of participants.This is not the same as creating a 97% antibody response.The article goes on to say that it's part of a mutli-step process to create immunity, so it seems this initial shot is not enough.This needs more clarity from someone with expertise in the field.